TY - JOUR T1 - Statins: a new approach to combat temozolomide chemoresistance in glioblastoma JF - Journal of Investigative Medicine JO - J Investig Med SP - 1083 LP - 1087 DO - 10.1136/jim-2018-000874 VL - 66 IS - 8 AU - Shahla Shojaei AU - Javad Alizadeh AU - James Thliveris AU - Navid Koleini AU - Elissavet Kardami AU - Grant M Hatch AU - Fred Xu AU - Sabine Hombach-Klonisch AU - Thomas Klonisch AU - Saeid Ghavami Y1 - 2018/12/01 UR - http://hw-f5-jim.highwire.org/content/66/8/1083.abstract N2 - Patients with glioblastoma multiforme (GBM) have an average life expectancy of approximately 15 months. Recently, statins have emerged as a potential adjuvant cancer therapy due to their ability to inhibit cell proliferation and induce apoptosis in many types of cancer. The exact mechanisms that mediate the inhibitory actions of statins in cancer cells are largely unknown. The purpose of this proceeding paper is to discuss some of the known anticancer effects of statins, while focusing on GBM therapy that includes adjunct therapy of statins with chemotherapeutic agents. ER -